Abstract
Background
Deoxypodophyllotoxin (DPT) is a semi-synthetic compound derived from the extract of Dysosma versipellis (Hance) M. Cheng, one of the most popular Chinese herbal medicines. The present study evaluates the in vitro cytotoxicity of DPT on a wide panel of human cancer cell lines and investigates its molecular mechanism of action on high grade glioma U-87 MG and SF126 cells.
Methods
The growth inhibitory effect of DPT on different types of human cancer cells was measured by the Cell Counting Kit-8 (CCK-8) assay. For the elucidation of the nature of the cellular response to DPT-treatment; flow cytometry-based assays, light and fluorescent microscopy, caspase colorimetric and inhibition assays, and Western blot analysis were performed.
Results
Our data show that DPT possesses a potent growth-inhibitory action, with IC50 values in nanomolar ranges. Cell cycle analysis revealed G2/M phase arrest in a dose- and time-dependent manner before cell death occurred. Additional studies indicated that DPT induced G2 arrest in U-87 MG cells by decreasing the expression of Cdc2, cyclin B1, and Cdc25C proteins. In contrast, DPT failed to down-regulate these cell cycle regulatory molecules in SF126 glioblastoma cells and stopped the cell cycle at M phase. Interestingly, morphological changes and biochemical markers such as phosphatydylserine externalization, DNA fragmentation, and caspase activation, confirmed that DPT-treatment resulted in an induction of apoptosis in both examined cell lines via caspase-dependent pathways.
Conclusions
Taken together, our data demonstrated that DPT possesses a potent in vitro cytotoxic activity and exerts its effect via G2/M arrest and apoptosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011;103: 714–36.
Zülch KJ. Brain tumors; their biology and pathology. Berlin: Springer-Verlag; 1986.
CBTRUS Statistical Report. Statistical report: primary brain tumors in the United States, 2000–2004. Chicago: Central Brain Tumor Registry of the United States; 2008 Available from: https://doi.org/www.cbtrus.org.
Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006;12:5288–97.
Affronti ML, Heery CR, Herndon 2nd JE, Rich JN, Reardon DA, Desjardins A, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmus-tine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009;115:3501–11.
Dall’Acqua S, Giorgetti M, Cervellati R, Innocenti G. Deoxypodophyllotoxin content and antioxidant activity of aerial parts of Anthriscus sylvestris Hoffm. Z Naturforsch C 2006;61:658–62.
van Maanen JM, Retel J, de Vries J, Pinedo HM. Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 1988;80:1526–33.
Shah JC, Chen JR, Chow D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm Res 1989;6:408–12.
Imbert TF. Discovery of podophyllotoxins. Biochimie 1998;80:207–22.
Zhou J, Xie G, Yan X. Encyclopedia of traditional Chinese medicines. Vol. 5 – molecular structures, pharmacological activities, natural sources and applications. New York: Springer; 2011.
Jiangsu New Medical College. Dictionary of Chinese traditional medicine. Shanghai: Shanghai Science and Technology Press; 1986.
Jiang RW, Zhou JR, Hon PM, Li SL, Zhou Y, Li LL, et al. Lignans from Dysosma versipellis with inhibitory effects on prostate cancer cell lines. J Nat Prod 2007;70:283–6.
Yu PZ, Wang LP, Chen ZN. A new podophyllotoxin-type lignan from Dysosma versipellis var. tomentosa. J Nat Prod 1991;54:1422–4.
Shang MY, Xu LS, Li P, Xu GJ, Wang YX, Cai SQ. Study on pharmacodynamics of Chinese herbal drug Guijiu and its lignan. Chin Tradit Herb Drugs 2002;33(8):722–4.
Wigley DB. Structure and mechanism of DNA topoisomerases. Annu Rev Biophys Biomol Struct 1995;24:185–208.
Rassmann I, Thodtmann R, Mross M, Huttmann A, Berdel WE, Manegold C, et al. Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. Invest New Drugs 1998;16:319–24.
Ayres DC, Loike JD. Lignans: chemical, biological and clinical properties. In: Chemistry and pharmacology of natural products. Cambridge, UK: Cambridge University Press; 1990.
Ankarcrona M, Dypbukt JM, Bonfoco E, Zhivotovsky B, Orrenius S, Lipton SA, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995;15: 961–73.
Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39–51.
Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007;28:2137–46.
Thornberry NA. Interleukin-1 beta converting enzyme. Methods Enzymol 1994;244:615–31.
Al-Rubeai M, Fussenegger M. Apoptosis. Kluwer Academic Publishers; 2004.
Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997;411:77–82.
Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetra-ethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 1993;197:40–5.
Islam MN, Iskander MN. Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem 2004;4:1077–104.
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253–65.
Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008;14:1610–7.
Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990;344:503–8.
Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 2002;9:1287–93.
Ohi R, Gould KL. Regulating the onset of mitosis. Curr Opin Cell Biol 1999;11:267–73.
Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;l 13:261–91.
Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639–49.
Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retino-blastoma protein recruits histone deacetylase to repress transcription. Nature 1998;391:597–601.
Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA. p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol 2000;20:4210–23.
Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413–50.
Hacker G. The morphology of apoptosis. Cell Tissue Res 2000;301:5–17.
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37–43.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Guerram, M., Jiang, ZZ., Sun, L. et al. Antineoplastic effects of deoxypodophyllotoxin, a potent cytotoxic agent of plant origin, on glioblastoma U-87 MG and SF126 cells. Pharmacol. Rep 67, 245–252 (2015). https://doi.org/10.1016/j.pharep.2014.10.003
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2014.10.003